Fulvestrant

CAS 129453-61-8 14 current records 2 historicalSmall Molecule

Who holds supplier records for Fulvestrant? 14 organisations hold a current record for Fulvestrant: an active US FDA Type II Drug Master File or a CEP. A further 2 organisations have only historical (inactive) DMF filings. 9 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (5), Italy (4), Taiwan (1), Netherlands (1) and 3 other countries (3).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Fulvestrant: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/fulvestrant

Reading the evidence

  • 14 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Fulvestrant expires 17 May 2034. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (14)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Fulvestrant. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Fulvestrant sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (9)

Certificates of Suitability on the EDQM register for Fulvestrant, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 13 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
MINAKEM HIGH POTENT Mont-Saint-GuibertBE
CEP 2024-002 - Rev 01
Fulvestrant
Sept 2026—
CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO., LTD. ChongqingCN
CEP 2025-060 - Rev 00
Fulvestrant
May 2026—
INDUSTRIALE CHIMICA S.R.L. SaronnoIT
CEP 2025-324 - Rev 00
Fulvestrant, Process 2
Sept 2025Inspected Oct 2025
Italy
TAPI NL B.V. AmsterdamNL
CEP 2013-255 - Rev 03
Fulvestrant
Jul 2025—
SCINOPHARM TAIWAN LTD. Shan-HuaTW
CEP 2015-338 - Rev 02
Fulvestrant
Sept 2024—
SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. LianyungangCN
CEP 2021-061 - Rev 01
Fulvestrant
Jun 2024—
WAVELENGTH ENTERPRISES LTD. Petah TikvaIL
CEP 2017-093 - Rev 03
Fulvestrant
Mar 2024—
FARMABIOS S.p.A Gropello CairoliIT
R1-CEP 2016-169 - Rev 00
Fulvestrant
Feb 2023—
STERLING S.p.A. Solomeo Di CorcianoIT
R1-CEP 2013-031 - Rev 01
Fulvestrant, Code 205418
Dec 2022—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (2)

Organisations whose Type II DMFs for Fulvestrant are no longer active. These show a past filing, not current supply.

Show all 2 historical records
  • France · Inactive DMF 26893 · filed Mar 2014
  • Teva Pharmaceutical Industries Ltd.
    Israel · Inactive DMF 22174 · filed Nov 2008

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (16 listed products contain Fulvestrant). The latest listed patent expires 17 May 2034. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Fulvestrant is an estrogen receptor antagonist used in the treatment of hormone receptor-positive metastatic breast cancer. It binds to estrogen receptors and promotes their degradation, thereby inhibiting their biological activity.

Chemical identity

IUPAC name
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
Canonical SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
InChIKey
VWUXBMIQPBEWFH-WCCTWKNTSA-N
Synonyms
Faslodex API, faslodex, ici 182,780, ici-182780, nsc-759879, zd-9238, zd9238

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Estrogen Receptor Antagonist
Mechanism of action
Estrogen Receptor Antagonists; Selective Estrogen Receptor Modulators

Therapeutic areas

OncologyBreast Cancer

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Fulvestrant?

14 organisations hold an active US FDA Type II Drug Master File or a CEP for Fulvestrant: CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO LTD (China), Farmabios S.p.A. (Italy), INDUSTRIALE CHIMICA SRL (Italy), SCINOPHARM TAIWAN LTD (Taiwan), SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD (China), STERLING SPA (Italy), TAPI NL BV (Netherlands) and WAVELENGTH ENTERPRISES LTD (Israel), and 6 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Fulvestrant Drug Master Files are active?

CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO LTD (DMF 40899), Farmabios S.p.A. (DMF 32949), INDUSTRIALE CHIMICA SRL (DMF 29104), SCINOPHARM TAIWAN LTD (DMF 22611), SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD (DMF 33902), STERLING SPA (DMF 26855), TAPI NL BV (DMF 26835) and WAVELENGTH ENTERPRISES LTD (DMF 29446) and 5 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Fulvestrant records mean?

2 organisations have only inactive Type II DMFs for Fulvestrant. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Fulvestrant have a European Certificate of Suitability?

Yes. 9 organisations hold a valid CEP for Fulvestrant on the EDQM register, including MINAKEM HIGH POTENT Mont-Saint-Guibert (BE), CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO., LTD. Chongqing (CN), INDUSTRIALE CHIMICA S.R.L. Saronno (IT), TAPI NL B.V. Amsterdam (NL), SCINOPHARM TAIWAN LTD. Shan-Hua (TW) and SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. Lianyungang (CN) and 3 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Fulvestrant?

Yes. The latest patent listed for an approved US product containing Fulvestrant expires 17 May 2034, across 16 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Fulvestrant supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Fulvestrant?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.